Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol

[1]  W. Hiatt,et al.  Effect of beta-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. , 1985, Circulation.

[2]  L. Endrenyi,et al.  Plasma Concentration‐Response Relationships of Two Formulations of Propranolol , 1985, Journal of clinical pharmacology.

[3]  P. Hayes,et al.  The influence of captopril, the nitrates and propranolol on apparent liver blood flow. , 1985, British journal of clinical pharmacology.

[4]  M. Kendall,et al.  Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol. , 1984, British journal of clinical pharmacology.

[5]  D. Schneck,et al.  Mechanism by which hydralazine increases propranolol bioavailability , 1984, Clinical pharmacology and therapeutics.

[6]  R. Bellens,et al.  Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol. , 1984, British journal of clinical pharmacology.

[7]  J T Ahokas,et al.  Comparison of beta-adrenoceptor antagonists as modulators of drug metabolism: effect of lipophilicity on microsomal phase I and II reactions. , 1984, British journal of clinical pharmacology.

[8]  A. J. Byrne,et al.  Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions. , 1984, British journal of clinical pharmacology.

[9]  E. Middleton,et al.  Effect of food on hepatic blood flow: Implications in the “food effect” phenomenon , 1983, Clinical pharmacology and therapeutics.

[10]  K. Borow,et al.  Sensitivity of End‐systolic Pressure‐Dimension and Pressure‐Volume Relations to the Inotropic State in Humans , 1982, Circulation.

[11]  H. Dargie,et al.  Nifedipine and propranolol: a beneficial drug interaction. , 1981, The American journal of medicine.

[12]  A. Mclean,et al.  Interaction between oral propranolol and hydralazine , 1980, Clinical pharmacology and therapeutics.

[13]  P. Routledge,et al.  Clinical Pharmacokinetics of Propranolol , 1979, Clinical pharmacokinetics.

[14]  P. McNamara,et al.  Food, splanchnic blood flow, and bioavailability of drugs subject to first‐pass metabolism , 1978, Clinical pharmacology and therapeutics.

[15]  R. Branch,et al.  Biological determinants of propranolol disposition in man , 1978, Clinical pharmacology and therapeutics.

[16]  D. Shand,et al.  Plasma concentrations and the time‐course of beta blockade due to propranolol , 1975, Clinical pharmacology and therapeutics.

[17]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[18]  K. Poulsen,et al.  An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. , 1974, The Journal of clinical endocrinology and metabolism.

[19]  H. L. Price,et al.  Control of the Splanchnic Circulation in Man: ROLE OF BETA‐ADRENERGIC RECEPTORS , 1967, Circulation research.

[20]  R. J. Whitney,et al.  The measurement of volume changes in human limbs , 1953, The Journal of physiology.

[21]  R. Towart,et al.  Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552). , 1980, Arzneimittel-Forschung.

[22]  R. Branch,et al.  Propranolol Disposition in Chronic Liver Disease: A Physiological Approach , 1976, Clinical pharmacokinetics.